Widespread Cardiovascular MDx and PGx Still Awaiting 'Prime Time' | GenomeWeb

NEW YORK (GenomeWeb) — Despite sustained interest among researchers and diagnostics developers in advancing molecular tests to personalize cardiovascular care, integration of such tools into clinical practice is happening slowly where at all.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.